含蛋白酶抑制剂的直接抗病毒药物与转氨酶升高风险增加相关,但不增加肝功能障碍或失代偿风险
本研究为倾向性评分匹配的队列研究,纳入18,498例接受直接抗病毒药物(DAA)治疗的丙型肝炎患者,比较含蛋白酶抑制剂(PI)方案与非PI方案对急性肝损伤三项结局的风险。结果显示,无论基线FIB-4分组如何,PI方案均增加ALT>200 U/L的风险,但未增加严重肝功能障碍或肝失代偿风险。
要点
- 含PI的DAA方案增加ALT>200 U/L风险,但不增加严重肝功能障碍或肝失代偿风险。
- 基线FIB-4≤3.25者,PI方案ALT>200 U/L的HR为3.98(95%CI 2.37-6.68)。
- 基线FIB-4>3.25者,PI方案ALT>200 U/L的HR为2.15(95%CI 1.09-4.26)。
核心结论
- 含PI的DAA方案与ALT升高风险增加相关,但严重肝功能障碍和肝失代偿风险与非PI方案无差异。
研究设计与样本
- cohort研究,纳入18,498例接受DAA治疗的1945-1965年退伍军人出生队列患者(2014-2019),按倾向性评分1:1匹配含PI方案与非PI方案。
主要发现
- 基线FIB-4≤3.25者,PI方案相比非PI方案ALT>200 U/L的HR为3.98(95%CI 2.37-6.68),严重肝功能障碍HR为0.67(95%CI 0.19-2.39),肝失代偿HR为1.01(95%CI 0.29-3.49)。
- 基线FIB-4>3.25者,PI方案相比非PI方案ALT>200 U/L的HR为2.15(95%CI 1.09-4.26),严重肝功能障碍HR为1.23(95%CI 0.64-2.38),肝失代偿HR为0.87(95%CI 0.41-1.87)。
关键数值与推荐
- ALT>200 U/L定义为丙氨酸氨基转移酶升高超过200 U/L。
- 严重肝功能障碍定义为凝血障碍伴高胆红素血症。
临床怎么用
- 使用含PI的DAA方案时应监测ALT,但无需因担忧严重肝功能障碍或肝失代偿而避免使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Cases of acute liver injury (ALI) have been reported among chronic HCV-infected patients receiving protease inhibitor (PI)-based direct-acting antiviral (DAA) regimens, but no analyses have compared the risk of ALI in patients receiving PI- vs. non-PI-based DAAs. Thus, we compared the risk of 3 ALI outcomes between patients (by baseline Fibrosis-4 [FIB-4] group) receiving PI-based or non-PI-based DAAs. METHODS: We conducted a cohort study of 18,498 patients receiving PI-based DAA therapy (paritaprevir/ritonavir/ombitasvir±dasabuvir, elbasvir/grazoprevir, glecaprevir/pibrentasvir) matched 1:1 on propensity score to those receiving non-PI-based DAAs (sofosbuvir/ledipasvir, sofosbuvir/velpatasvir) in the 1945-1965 Veterans Birth Cohort (2014-2019). During exposure to DAA therapy, we determined development of: i) alanine aminotransferase (ALT) >200 U/L, ii) severe hepatic dysfunction (coagulopathy with hyperbilirubinemia), and iii) hepatic decompensation. We used Cox regression to determine hazard ratios (HRs) with 95% CIs for each ALI outcome within groups defined by baseline FIB-4 (≤3.25; >3.25). RESULTS: Among patients with baseline FIB-4 ≤3.25, those receiving PIs had a higher risk of ALT >200 U/L (HR 3.98; 95% CI 2.37-6.68), but not severe hepatic dysfunction (HR 0.67; 95% CI 0.19-2.39) or hepatic decompensation (HR 1.01; 95% CI 0.29-3.49), compared to those receiving non-PI-based regimens. For those with baseline FIB-4 >3.25, those receiving PIs had a higher risk of ALT >200 U/L (HR, 2.15; 95% CI 1.09-4.26), but not severe hepatic dysfunction (HR, 1.23 [0.64-2.38]) or hepatic decompensation (HR, 0.87; 95% CI 0.41-1.87), compared to those receiving non-PI-based regimens CONCLUSION: While risk of incident ALT elevations was increased in those receiving PI-based DAAs in both FIB-4 groups, the risk of severe hepatic dysfunction and hepatic decompensation did not differ between patients receiving PI- or non-PI-based DAAs in either FIB-4 group. LAY SUMMARY: Cases of liver injury have been reported among patients treated with protease inhibitor-based direct-acting antivirals for hepatitis C infection, but it is not clear if the risk of liver injury among people starting these drugs is increased compared to those starting non-protease inhibitor-based therapy. In this study, patients receiving protease inhibitor-based treatment had a higher risk of liver inflammation than those receiving a non-protease inhibitor-based treatment, regardless of the presence of pre-treatment advanced liver fibrosis/cirrhosis. However, the risk of severe liver dysfunction and decompensation were not higher for patients treated with protease inhibitor-based regimens.
引用
- Torgersen J, Newcomb CW, Carbonari DM, et al. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. J Hepatol. 2021. PMID: 34333102. doi:10.1016/j.jhep.2021.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。